Advancing AlzeCure

Stockholm-based AlzeCure Pharma AB is planning to raise SEK200 million ($22 million) in an IPO on NASDAQ First North Premier to bring both arms of its Alzheimer’s disease portfolio to the clinic.

In a prospectus filed on Nov. 6, the company announced plans to sell 14.3 million shares at SEK14 and said it expects to begin trading Nov. 28.

The company’s preclinical pipeline targets two different populations of Alzheimer’s patients: early stage presymptomatic patients and symptomatic mild-to-moderate patients.

AlzeCure CEO Johan Sandin told BioCentury the early...